William Blair & Company
ANIK icon

William Blair & Company’s Anika Therapeutics ANIK Stock Holding History

William Blair & Company’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,985
Closed -$219K – 1726
2019
Q3 		$219K Sell
3,985
-2,108
-35% -$108K ﹤0.01% 1233
2019
Q2 		$247K Buy
+6,093
New +$222K ﹤0.01% 1226
2019
Q1 		– Sell
-7,154
Closed -$240K – 1703
2018
Q4 		$240K Sell
7,154
-191
-3% -$6.89K ﹤0.01% 1175
2018
Q3 		$310K Buy
7,345
+168
+2% +$6.64K ﹤0.01% 1129
2018
Q2 		$230K Hold
7,177
– – ﹤0.01% 1221
2018
Q1 		$357K Buy
7,177
+1,157
+19% +$65.4K ﹤0.01% 1026
2017
Q4 		$325K Sell
6,020
-1,615
-21% -$89.4K ﹤0.01% 1101
2017
Q3 		$443K Sell
7,635
-656
-8% -$34.3K ﹤0.01% 968
2017
Q2 		$409K Buy
8,291
+953
+13% +$43.9K ﹤0.01% 1049
2017
Q1 		$319K Buy
+7,338
New +$350K ﹤0.01% 1050

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

William Blair & Company's ANIK Position: Q4 2019 in Review

William Blair & Company sold out of Anika Therapeutics (ANIK) in Q4 2019, closing a stake of 3,985 shares — an estimated $219K sold.

William Blair & Company first reported a position in ANIK in Q1 2017 and held it in 10 quarters. The position peaked at $443K in Q3 2017. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

  • William Blair & Company reported no remaining Anika Therapeutics position as of Q4 2019 after selling out during the quarter.
  • William Blair & Company sold 3,985 Anika Therapeutics shares in Q4 2019, an estimated $219K.
  • William Blair & Company first reported a position in Anika Therapeutics in Q1 2017 and held it in 10 quarters.
  • William Blair & Company's Anika Therapeutics position peaked at $443K in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on William Blair & Company's 13F filing for Q4 2019, filed 13 Feb 2020.